C:\STNEXP4\QUERIES\09980475 (species).str





chain nodes :
20 22
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
chain bonds :
1-10 7-16
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18 14-15
15-16 16-17 17-18
exact bonds :
1-10 7-16
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18 14-15
15-16 16-17 17-18
isolated ring systems :
containing 1 : 7 : 13 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 20:CLASS 21:CLASS 22:CLASS
23:CLASS

```
=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end


=> screen 1840

L20   SCREEN CREATED

=> screen 2016 OR  2026 OR  2039 OR  2040 OR  2045 OR  2047

L21   SCREEN CREATED

=>
Uploading C:\STNEXP4\QUERIES\09980475 (species).str

L22     STRUCTURE UPLOADED -

=> que L22 AND L20 NOT L21

L23  QUE L22 AND L20 NOT L21

=> d 123
L23 HAS NO ANSWERS
L20             SCR 1840
L21             SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
L22             STR
```




```
Structure attributes must be viewed using STN Express query preparation.
L23             QUE  L22 AND L20 NOT L21


=> s l23 sss sam
SAMPLE SEARCH INITIATED 17:00:13 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    437 TO ITERATE

100.0% PROCESSED     437 ITERATIONS                          48 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         7486 TO     9994
PROJECTED ANSWERS:             545 TO     1375

L24          48 SEA SSS SAM L22 AND L20 NOT L21

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end
```

```
=> screen 1840

L25   SCREEN CREATED

=> screen 2016 OR  2026 OR  2039 OR  2040 OR  2045 OR  2047

L26   SCREEN CREATED

=>
Uploading C:\STNEXP4\QUERIES\09980475 (species).str

L27     STRUCTURE UPLOADED

=> que L27 AND L25 NOT L26

L28  QUE L27 AND L25 NOT L26

=> d 128
L28 HAS NO ANSWERS
L25             SCR 1840
L26             SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
L27             STR
```




```
Structure attributes must be viewed using STN Express query preparation.
L28             QUE  L27 AND L25 NOT L26


=> s l28 sss sam
SAMPLE SEARCH INITIATED 17:01:52 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    437 TO ITERATE

100.0% PROCESSED     437 ITERATIONS                          35 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         7486 TO     9994
PROJECTED ANSWERS:             346 TO     1054

L29          35 SEA SSS SAM L27 AND L25 NOT L26

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end
```

```
=> screen 1840

L30   SCREEN CREATED

=> screen 2016 OR  2026 OR  2039 OR  2040 OR  2045 OR  2047

L31   SCREEN CREATED

=>
Uploading C:\STNEXP4\QUERIES\09980475 (species).str

L32     STRUCTURE UPLOADED

=> que L32 AND L30 NOT L31

L33  QUE L32 AND L30 NOT L31

=> d 133
L33 HAS NO ANSWERS
L30             SCR 1840
L31             SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
L32             STR
```




```
Structure attributes must be viewed using STN Express query preparation.
L33             QUE  L32 AND L30 NOT L31


=> s l33 sss sam
SAMPLE SEARCH INITIATED 17:03:08 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    437 TO ITERATE

100.0% PROCESSED     437 ITERATIONS                          9 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         7486 TO     9994
PROJECTED ANSWERS:               9 TO      360

L34           9 SEA SSS SAM L32 AND L30 NOT L31

=> s l33 sss ful
FULL SEARCH INITIATED 17:03:17 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   8640 TO ITERATE

100.0% PROCESSED    8640 ITERATIONS                        143 ANSWERS
```

SEARCH TIME: 00.00.01

L35 143 SEA SSS FUL L32 AND L30 NOT L31

=> s l35
L36 10 L35

=> d l36 1-10 bib,ab,hitstr

L36 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2003 ACS
AN 2003:300891 CAPLUS
DN 138:321134
TI Preparation of biphenylylpyridine derivatives as dihydroorotate dehydrogenase inhibitors
IN Arimura, Akinori; Kishino, Junji; Tanimoto, Norihiko
PA Shionogi & Co., Ltd., Japan
SO PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003030905	A1	20030417	WO 2002-JP10030	20020927

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI JP 2001-305557 A 20011001
OS MARPAT 138:321134
AB The title compds. I [wherein R1 and R4 = independently alkyl or alkoxy; R2 and R3 = independently H or alkyl; R5 = H or halo; R6 = H or OH; X1 and X2 = independently O or NH] and prodrugs, pharmaceutically acceptable salts, and solvates thereof are prepd. as dihydroorotate dehydrogenase inhibitors. I are useful for the treatment of cancer, virus infection, chronic articular rheumatism, and transplant rejection (no data). For example, compd. II was prepd. in a multi-step synthesis. II showed IC50 of 17 ng/mL against human U-937 cell. Formulations contg. I as an active ingredient were also described.
IT **234423-87-1P 234429-28-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of biphenylylpyridine derivs. as dihydroorotate dehydrogenase inhibitors)
RN 234423-87-1 CAPLUS
CN Acetic acid, hydroxy-, [[[[2-fluoro-2',5'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl][1,1'-biphenyl]-4-yl](3-methyl-2-butenyl)amino]carbonyl]oxy]methyl ester (9CI) (CA INDEX NAME)



RN 234429-28-8 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 2-fluoro-2',5'-dimethyl-N-(3-methyl-2-butenyl)-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



IT **234429-40-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of biphenylylpyridine derivs. as dihydroorotate dehydrogenase inhibitors)
RN 234429-40-4 CAPLUS
CN Carbamic acid, [2-fluoro-2',5'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl][1,1'-biphenyl]-4-yl](3-methyl-2-butenyl)-, chloromethyl ester (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2003 ACS
AN 2002:632833 CAPLUS
DN 137:169427
TI 3-Pyridyloxymethyl heterocyclic ether compounds with nicotinic cholinergic activity, useful in controlling chemical synaptic transmission.
IN Lin, Nan-Horng; He, Yun; Holladay, Mark W.; Ryther, Keith; Li, Yihong; Bai, Hao
PA Abbott Laboratories, USA
SO U.S., 66 pp., Cont.-in-part of U.S. 6,127,386.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6437138	B1	20020820	US 2000-472399	20000301
	US 5629325	A	19970513	US 1996-660044	19960606
	US 6127386	A	20001003	US 1997-844540	19970418
PRAI	US 1996-660044	A2	19960606		
	US 1997-844540	A2	19970418		

OS MARPAT 137:169427
AB Novel 3-pyridyloxymethyl heterocyclic ether compds. I and their pharmaceutically acceptable salts or prodrugs are disclosed [wherein: n = 1-3; R1 = H, allyl, alkyl; R2 = H, alkyl, F, Cl, ethenyl, Ph; L = bond, alkylene, C.tplbond.C-alkyl, (CH:CH)1-2-alkyl, CH:CHCO-alkyl, CO-alkyl, CH2-M-CO--alkyl; M = CH2 or NH; R3 = H, alkyl, alkenyl, haloalkyl, hydroxyalkyl, alkoxy, (di)(alkyl)amino, (un)substituted aryl or heteroaryl; or LR3 = OCH2R4; R4 = CH2OMe, dialkylamino, (un)substituted aryl or heteroaryl; with provisos]. The compds. are selective and potent ligands at neuronal nicotinic cholinergic channel receptors. Over 200 examples are given. For example, vinylation of 3-(1-BOC-2-(S)-pyrrolidinylmethoxy)-5-bromo-6-chloropyridine (prepn. given) with vinyltributyltin in the presence of Pd(PPh3)4 in PhMe (85%), followed by deprotection and salification with HCl in dioxane (86%), gave title substance II.bul.HCl. This substance bound to neuronal nicotinic receptors in vitro with a Ki of 0.035 nM. Compds. I also activated or inhibited neuronal nicotinic receptor channels in IMR-32 cells in vitro.
IT **299894-37-4P**, 5-(4'-Nitro-4-biphenylyl)-3-(2-(S)-azetidinylmethoxy)pyridine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of pyridyloxymethyl heterocyclic ethers as nicotinic cholinergic receptor ligands)
RN 299894-37-4 CAPLUS
CN Pyridine, 3-[(2S)-2-azetidinylmethoxy]-5-(4'-nitro[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2003 ACS
AN 2001:762806 CAPLUS
DN 135:322727
TI Oil-in-water microemulsions containing tricyclic compounds or preconcentrates thereof
IN Kawakami, Kohsaku; Yoshikawa, Takayoshi
PA Shionogi + Co., Ltd., Japan
SO PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001076582	A1	20011018	WO 2001-JP2617	20010329

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI JP 2000-102933 A 20000405
OS MARPAT 135:322727
AB Disclosed are microemulsions which contain a tricyclic compd., pharmaceutically acceptable salts thereof, and solvates of both, a monoester of glycerol with a fatty acid and/or a monoester of propylene glycol with a fatty acid, and a surfactant; and preconcs. of the microemulsions. A microemulsion preconc. for oral administration contained 2-fluoro-2',5'-dimethyl-N-(3-methyl-2-butenyl)-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- [1,1'-biphenyl]-4-amine 50, Homotex PT 400, Sefsol-228 400, and Tween-80 359 mg.
IT **234429-28-8**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(microemulsions contg. tricyclic compds. and solubilizers and surfactants)
RN 234429-28-8 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 2-fluoro-2',5'-dimethyl-N-(3-methyl-2-butenyl)-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2003 ACS
AN 2001:747580 CAPLUS
DN 135:278052
TI Oily compositions containing highly fat-soluble drugs
IN Nishihara, Yoshitaka; Kinoshita, Haruki; Yoshikawa, Takayoshi
PA Shionogi + Co., Ltd., Japan
SO PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001074331	A1	20011011	WO 2001-JP2621	20010329
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001044614	A5	20011015	AU 2001-44614	20010329
	EP 1273287	A1	20030108	EP 2001-917589	20010329
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRAI	JP 2000-102272	A	20000404		
	WO 2001-JP2621	W	20010329		

OS MARPAT 135:278052
AB Disclosed are oily compns. which contain as the principal agent highly fat-sol. drugs, pharmaceutically acceptable salts and solvates thereof and further contain (1) a triester of glycerol with a medium-chain fatty acid and/or an ester of propylene glycol with a medium-chain fatty acid, (2) a triester of glycerol with a long-chain fatty acid, and (3) a surfactant. An emulsion contained 3''-fluoro-2',3',5',6'-tetramethyl-N-(3-methyl-2-butenyl)-4''-[(3-methyl-2-butenyl)oxy]-[1,1':4',1''-terphenyl]-4-amine 10 %, Miglyol-812 60 %, avocado oil 10 %, and sorbitan monopalmitate 20 %.
IT **234429-28-8**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oily compns. contg. highly fat-sol. drugs)
RN 234429-28-8 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 2-fluoro-2',5'-dimethyl-N-(3-methyl-2-butenyl)-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2003 ACS
AN 2001:78356 CAPLUS
DN 134:131548
TI Preparation of tricyclic compounds as allergy inhibitors, immunosuppressants, and IgE production inhibitors
IN Tanimoto, Norihiko; Inagaki, Masanao
PA Shionogi & Co., Ltd., Japan
SO PCT Int. Appl., 363 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001007401	A1	20010201	WO 2000-JP4726	20000714
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2000060160	A5	20010213	AU 2000-60160	20000714
PRAI	JP 1999-209298	A	19990723		
	JP 1999-211702	A	19990727		
	WO 2000-JP4726	W	20000714		

OS MARPAT 134:131548
AB The title compds. I [A, B and C are each an arom. carbo- or hetero-cycle or the like, with the proviso that when A is an optionally substituted five-membered heterocycle, W1 is a bond, the same applying in the case of B and W2 and that of C and W3; X and X' are each O, NH, or the like; Y is lower alkyl, lower alkenyl, or the like; V1 and V2 are each a single bond or the like; Ra and Rb are each hydrogen, lower alkyl, lower alkenyl, or the like; further details on Ra and Rb are given ; n is 0 to 2] are prepd. Several compds. of this invention at 40 mg/kg/day orally for 10 days suppressed the prodn. of IgE in a mouse model. Formulations are given.
IT **321981-93-5P 321981-94-6P 321981-97-9P**
321981-98-0P 321981-99-1P 321982-00-7P
321982-01-8P 321982-08-5P 321982-09-6P
321982-10-9P 321982-11-0P 321982-12-1P
321982-13-2P 321982-29-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of tricyclic compds. as allergy inhibitors, immunosuppressants, and IgE prodn. inhibitors)
RN 321981-93-5 CAPLUS
CN 2-Propanone, O-[5-[2'-fluoro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-2-pyridinyl]oxime (9CI) (CA INDEX NAME)



RN 321981-94-6 CAPLUS
CN 3-Pentanone, O-[5-[2'-fluoro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-2-pyridinyl]oxime (9CI) (CA INDEX NAME)



RN 321981-97-9 CAPLUS
CN 2-Butanone, O-[5-[2'-fluoro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-2-pyridinyl]oxime (9CI) (CA INDEX NAME)



RN 321981-98-0 CAPLUS
CN Ethanimidic acid, N-[[5-[2'-fluoro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-2-pyridinyl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 321981-99-1 CAPLUS
CN Cyclopentanone, O-[5-[2'-fluoro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-2-pyridinyl]oxime (9CI) (CA INDEX NAME)



RN 321982-00-7 CAPLUS
CN Cyclohexanone, O-[5-[2'-fluoro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-2-pyridinyl]oxime (9CI) (CA INDEX NAME)



RN 321982-01-8 CAPLUS
CN Ethanone, 1-phenyl-, O-[5-[2'-fluoro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-2-pyridinyl]oxime (9CI) (CA INDEX NAME)



RN 321982-08-5 CAPLUS
CN 2-Propanone, O-[5-(4'-amino-2'-fluoro-2,5-dimethyl[1,1'-biphenyl]-4-yl)-2-pyridinyl]oxime (9CI) (CA INDEX NAME)



RN 321982-09-6 CAPLUS
CN 2-Propanone, O-[5-[4'-(cyclohexylamino)-2'-fluoro-2,5-dimethyl[1,1'-biphenyl]-4-yl]-2-pyridinyl]oxime (9CI) (CA INDEX NAME)



RN 321982-10-9 CAPLUS
CN 2-Propanone, O-[5-[2'-fluoro-2,5-dimethyl-4'-[(phenylmethyl)amino][1,1'-biphenyl]-4-yl]-2-pyridinyl]oxime (9CI) (CA INDEX NAME)



RN 321982-11-0 CAPLUS
CN 2-Propanone, O-[5-[2,3,5,6-tetramethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-2-pyridinyl]oxime (9CI) (CA INDEX NAME)



RN 321982-12-1 CAPLUS
CN Ethanone, 1-phenyl-, O-[5-[2,3,5,6-tetramethyl-4'-[(3-methyl-2-

butenyl)amino][1,1'-biphenyl]-4-yl]-2-pyridinyl]oxime (9CI) (CA INDEX NAME)



RN 321982-13-2 CAPLUS
CN Ethanimidic acid, N-[[5-[2,3,5,6-tetramethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-2-pyridinyl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 321982-29-0 CAPLUS
CN 2-Propanone, O-[5-[3'-fluoro-2,3,5,6-tetramethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-2-pyridinyl]oxime (9CI) (CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2003 ACS
AN 2001:78224 CAPLUS
DN 134:131433
TI Preparation of tricyclic compounds as inhibitors of cell differentiation into Th2 cells
IN Arimura, Akinori; Kawada, Kenji
PA Shionogi & Co., Ltd., Japan
SO PCT Int. Appl., 102 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001007032	A1	20010201	WO 2000-JP4725	20000714
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	BR 2000012697	A	20020409	BR 2000-12697	20000714
	EP 1206935	A1	20020522	EP 2000-946316	20000714
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	NO 2001006401	A	20020123	NO 2001-6401	20011221
PRAI	JP 1999-209298	A	19990723		
	WO 2000-JP4725	W	20000714		

OS MARPAT 134:131433
AB The title compds. I [rings A, B and C are each an arom. carbon ring, a heterocycle, etc.; X represents a single bond, O, CH2, NH, SO, etc.; Y represents hydrogen, optionally substituted lower alkyl, optionally substituted lower alkenyl, etc.; and V1 and V2 represent each a single bond, O, NH, OCH2, etc.; when ring A, B, or C is (un)substituted 5-membered heterocyclic ring, W1, W2, W3 = bond] are prepd. Compds. of this invention at 40 mg/kg gave significant inhibition of Th0 cell differentiation into Th2 cells. Formulations are given.
IT **234426-58-5P 234427-63-5P 234427-80-6P**
234429-28-8P 321981-93-5P 322477-27-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of tricyclic compds. as inhibitors of cell differentiation into Th2 cells)
RN 234426-58-5 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 2',5'-dimethyl-N-(3-methyl-2-butenyl)-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234427-63-5 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 3'-methoxy-2',5',6'-trimethyl-N-(3-methyl-2-butenyl)-4'-[6-(2,2,2-trifluoroethoxy)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234427-80-6 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 2',3',6'-trimethyl-N-(3-methyl-2-butenyl)-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234429-28-8 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 2-fluoro-2',5'-dimethyl-N-(3-methyl-2-butenyl)-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 321981-93-5 CAPLUS

CN 2-Propanone, O-[5-[2'-fluoro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-2-pyridinyl]oxime (9CI) (CA INDEX NAME)



RN 322477-27-0 CAPLUS
CN Acetic acid, hydroxy-, [[[[3-fluoro-2',5'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl][1,1'-biphenyl]-4-yl](3-methyl-2-butenyl)amino]carbonyl]oxy]methyl ester (9CI) (CA INDEX NAME)



IT **322477-32-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of tricyclic compds. as inhibitors of cell differentiation into Th2 cells)
RN 322477-32-7 CAPLUS
CN Carbamic acid, [3-fluoro-2',5'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl][1,1'-biphenyl]-4-yl](3-methyl-2-butenyl)-, chloromethyl ester (9CI) (CA INDEX NAME)



L36 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2003 ACS
AN 2001:63977 CAPLUS
DN 134:116240
TI Preparation of tricyclic compounds bearing acyloxymethoxycarbonyl pendants as prodrugs for allergy inhibitors and immunosuppressants
IN Aono, Katsutoshi; Ichihashi, Teruhisa; Kugimiya, Akira
PA Shionogi + Co., Ltd., Japan
SO PCT Int. Appl., 103 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001005768	A1	20010125	WO 2000-JP4724	20000714
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2000060158	A5	20010205	AU 2000-60158	20000714
	EP 1219606	A1	20020703	EP 2000-946315	20000714
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
PRAI	JP 1999-204977	A	19990719		
	JP 1999-211702	A	19990727		
	JP 2000-84052	A	20000324		
	WO 2000-JP4724	W	20000714		

OS MARPAT 134:116240
AB Compds. of general formula (I) and their salts and solvates of both [wherein one of X and X1 is -N(CO2CR3R2O2CR1)- and the other is (CH2)s, O, NRA, -N(CO2CR3R2O2CR1), or S(O)p (wherein s and p is 0-2; R1 is lower alkyl substituted with carbamoyl, lower alkylcarbamoyl, carbamoyloxy, lower alkylcarbamoyloxy, acetylamino, or the like; and R2 and R3 are each hydrogen or lower alkyl); Y and Y1 are each optionally substituted lower alkyl, lower alkenyl, or lower alkynyl, cycloalkyl, cycloalkenyl, lower alkoxycarbonyl, the like; ring A, B and C are each an optionally substituted arom. carbocycle or an optionally substituted optionally benzene-fused 5- or 6-membered heterocycle; when ring A, B and C are optionally substituted 5-membered heterocyclic ring, W1, W2, and W3 are each a bond; and when both V1 and V2 are each a single bond, at least one ring A, B, and C is an arom. carbocyclic ring and at least one of them is a optionally substituted optionally benzene-fused 5- to 6-membered heterocycle], which are prodrugs for allergy inhibitors and immunosuppressants with improved oral absorbability, are prepd. These compds. suppress mitogenic and/or cytokine reactions and possess immunosuppressant and antiallergic activity, and their activated compds. in particular possess very potent inhibitory activity against proliferation of T and B cells and/or antibody-prodn. inhibitory activity. Thus, acylation of 3-(4'-amino-1,1'-biphenyl-4-yl)pyridine deriv. (II; R = H) with chloromethyl chloroformate in the presence of Et3N in Et2O at 0.degree. to room temp. for 4 h gave II (R = CO2CH2Cl) which was condensed with succinamic acid in the presence of K2CO3 and KBr in DMF with vigorously stirring at room temp. for 20 h gave II (R =

CO2CH2O2CCH2CH2CONH2) (III). III and II (R = Ac-Gly-Gly-OCH2O2C) were in vivo effective for inhibiting anti-ovalbumin antibody prodn. in rats with passive cutaneous anaphylaxis (PCA) reaction value of 0.8 and <0, resp., at 10 mg/kg p.o. vs. 6.7 for II (R = H).

IT **321439-04-7P 321439-05-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of tricyclic compds. bearing acyloxymethoxycarbonyl pendants as prodrugs for allergy inhibitors and immunosuppressants)

RN 321439-04-7 CAPLUS

CN Butanoic acid, 4-amino-4-oxo-, [[[[3'-methoxy-2',5',6'-trimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl][1,1'-biphenyl]-4-yl](3-methyl-2-butenyl)amino]carbonyl]oxy]methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

— CH═ CMe2

RN 321439-05-8 CAPLUS

CN Butanoic acid, 4-amino-4-oxo-, [[[[2-fluoro-2',5'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl][1,1'-biphenyl]-4-yl](1-methylethyl)amino]carbonyl]oxy]methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



IT **234429-28-8P 321438-93-1P 321438-94-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of tricyclic compds. bearing acyloxymethoxycarbonyl pendants as prodrugs for allergy inhibitors and immunosuppressants)

RN 234429-28-8 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 2-fluoro-2',5'-dimethyl-N-(3-methyl-2-butenyl)-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 321438-93-1 CAPLUS
CN Carbamic acid, [2-fluoro-2',5'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl][1,1'-biphenyl]-4-yl](1-methylethyl)-, chloromethyl ester (9CI) (CA INDEX NAME)



RN 321438-94-2 CAPLUS
CN Carbamic acid, [3'-methoxy-2',5',6'-trimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl][1,1'-biphenyl]-4-yl](3-methyl-2-butenyl)-, chloromethyl ester (9CI) (CA INDEX NAME)



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2003 ACS
AN 2000:699189 CAPLUS
DN 133:281694
TI 3-Pyridyloxymethyl heterocyclic ether compounds with nicotinic cholinergic activity, useful in controlling chemical synaptic transmission.
IN Lin, Nan-horng; He, Yun; Holladay, Mark W.; Ryther, Keith B.; Li, Yihong; Bai, Hao
PA Abbott Laboratories, USA
SO U.S., 74 pp., Cont.-in-part of U.S. Ser. No. 660,044.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6127386	A	20001003	US 1997-844540	19970418
	US 5629325	A	19970513	US 1996-660044	19960606
	JP 2002515038	T2	20020521	JP 1998-500686	19970604
	US 6437138	B1	20020820	US 2000-472399	20000301
PRAI	US 1996-660044	A2	19960606		
	US 1997-844540	A	19970418		
	WO 1997-US9167	W	19970604		

OS MARPAT 133:281694
AB Novel 3-pyridyloxymethyl heterocyclic ether compds. I and their pharmaceutically acceptable salts or prodrugs are disclosed [wherein: n = 1-3; R1 = H, allyl, C1-6 alkyl; R2 = H, C1-3 alkyl, F, Cl, ethenyl, Ph; L = bond, C1-6 alkylene, C.tplbond.C-(C0-6-alkyl), (CH:CH)1-2-(C0-6-alkyl), CH:CHCO-(C0-6-alkyl), CO-(C0-6-alkyl), CH2-M-CO-(C0-6-alkyl); M = CH2 or NH; R3 = H, C1-8 alkyl, C2-6 alkenyl, C1-6 haloalkyl, hydroxyalkyl, alkoxy, (di)(alkyl)amino, (un)substituted aryl or heteroaryl; or LR3 = OCH2R4; R4 = CH2OMe, dialkylamino, (un)substituted aryl or heteroaryl; with provisos]. Claims include compds. I, prepn. of I via certain halopyridine intermediates, pharmaceutical compns. contg. I, and use of I to control synaptic transmission. The compds. are selective and potent ligands at neuronal nicotinic cholinergic channel receptors. Over 200 examples are given, most including phys. data for I. For example, vinylation of 3-(1-BOC-2-(S)-pyrrolidinylmethoxy)-5-bromo-6-chloropyridine (prepn. given) with vinyltributyltin in the presence of Pd(PPh3)4 in PhMe (85%), followed by deprotection and salification with HCl in dioxane (86%), gave title substance II.HCl. This substance bound to neuronal nicotinic receptors in vitro with a Ki of 0.035 nM. Compds. I also activated or inhibited neuronal nicotinic receptor channels in IMR-32 cells in vitro.
IT **299894-37-4P**, 5-(4'-Nitro-4-biphenylyl)-3-(2-(S)-azetidinylmethoxy)pyridine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of pyridyloxymethyl heterocyclic ethers as nicotinic cholinergic receptor ligands)
RN 299894-37-4 CAPLUS
CN Pyridine, 3-[(2S)-2-azetidinylmethoxy]-5-(4'-nitro[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2003 ACS
AN 1999:495258 CAPLUS
DN 131:129907
TI Preparation and formulation of tricyclic compounds as immunosuppressants and allergy inhibitors
IN Tanimoto, Norihiko; Hasegawa, Yasushi; Haga, Nobuhiro
PA Shionogi & Co., Ltd., Japan
SO PCT Int. Appl., 298 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9938829	A1	19990805	WO 1999-JP297	19990126
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2318368	AA	19990805	CA 1999-2318368	19990126
	AU 9919837	A1	19990816	AU 1999-19837	19990126
	AU 742641	B2	20020110		
	EP 1052238	A1	20001115	EP 1999-900676	19990126
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 9908539	A	20001205	BR 1999-8539	19990126
	NO 2000003706	A	20000914	NO 2000-3706	20000719
	US 6562817	B1	20030513	US 2000-600790	20000721
PRAI	JP 1998-15554	A	19980128		
	WO 1999-JP297	W	19990126		

OS MARPAT 131:129907
AB The title compds. I [each of ring A, ring B and ring C is independently a substituted or unsubstituted arom. ring or a substituted or unsubstituted five or six-membered heterocycle which may be condensed with a benzene ring; when ring A, ring B and/or ring C is a substituted or unsubstituted five-membered heterocycle, W1, W2 and/or W3 represents a bond; X is O or NR1 (where R1 is hydrogen, a lower alkyl or the like); Y is hydrogen, a lower alkyl, a lower alkenyl or the like ; one of V1 and V2 is a single bond and the other is a single bond, O, etc.] are prepd. The title compd. II in vitro showed IC50 of 400 ng/mL against the growth of mouse EL4 cells. The inhibiting activities of compds. of this invention against the prodn. of IgE were also demonstrated.
IT **234429-40-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of tricyclic compds. as immunosuppressants and allergy inhibitors)
RN 234429-40-4 CAPLUS
CN Carbamic acid, [2-fluoro-2',5'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl][1,1'-biphenyl]-4-yl](3-methyl-2-butenyl)-, chloromethyl ester (9CI) (CA INDEX NAME)



IT **234423-87-1P 234426-05-2P 234426-38-1P**
234426-39-2P 234426-40-5P 234426-41-6P
234426-42-7P 234426-43-8P 234426-44-9P
234426-46-1P 234426-47-2P 234426-48-3P
234426-49-4P 234426-50-7P 234426-51-8P
234426-52-9P 234426-53-0P 234426-54-1P
234426-55-2P 234426-56-3P 234426-57-4P
234426-58-5P 234426-59-6P 234426-60-9P
234426-61-0P 234426-62-1P 234426-63-2P
234426-64-3P 234426-65-4P 234426-66-5P
234426-67-6P 234426-68-7P 234426-69-8P
234426-70-1P 234426-71-2P 234426-72-3P
234426-73-4P 234426-74-5P 234426-75-6P
234426-76-7P 234426-77-8P 234426-85-8P
234426-86-9P 234426-87-0P 234426-88-1P
234426-89-2P 234426-90-5P 234426-91-6P
234426-92-7P 234426-93-8P 234426-94-9P
234426-95-0P 234426-96-1P 234426-97-2P
234426-98-3P 234427-05-5P 234427-10-2P
234427-11-3P 234427-14-6P 234427-15-7P
234427-16-8P 234427-40-8P 234427-41-9P
234427-42-0P 234427-43-1P 234427-44-2P
234427-45-3P 234427-46-4P 234427-47-5P
234427-48-6P 234427-49-7P 234427-50-0P
234427-51-1P 234427-52-2P 234427-54-4P
234427-55-5P 234427-56-6P 234427-57-7P
234427-58-8P 234427-59-9P 234427-60-2P
234427-61-3P 234427-62-4P 234427-63-5P
234427-64-6P 234427-65-7P 234427-68-0P
234427-69-1P 234427-70-4P 234427-71-5P
234427-72-6P 234427-73-7P 234427-74-8P
234427-80-6P 234427-81-7P 234427-82-8P
234427-83-9P 234427-84-0P 234427-85-1P
234427-86-2P 234427-87-3P 234427-88-4P
234427-89-5P 234427-90-8P 234427-91-9P
234427-92-0P 234427-93-1P 234427-94-2P
234427-95-3P 234427-96-4P 234427-97-5P
234427-98-6P 234427-99-7P 234428-00-3P
234428-54-7P 234428-55-8P 234428-56-9P
234428-57-0P 234429-42-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of tricyclic compds. as immunosuppressants and allergy

inhibitors)

RN 234423-87-1 CAPLUS

CN Acetic acid, hydroxy-, [[[[2-fluoro-2',5'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl][1,1'-biphenyl]-4-yl](3-methyl-2-butenyl)amino]carbonyl]oxy]methyl ester (9CI) (CA INDEX NAME)



RN 234426-05-2 CAPLUS

CN [1,1'-Biphenyl]-4-amine, N,N,2',5'-tetramethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234426-38-1 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2-fluoro-2',5'-dimethoxy-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234426-39-2 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2-fluoro-2',5'-dimethoxy-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 234426-40-5 CAPLUS
CN Sulfamide, N-[2-fluoro-2',5'-dimethoxy-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl][1,1'-biphenyl]-4-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 234426-41-6 CAPLUS
CN Sulfamide, N-[2-fluoro-2',5'-dimethoxy-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl][1,1'-biphenyl]-4-yl]-N'-methyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 234426-42-7 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 2-fluoro-2',5'-dimethoxy-N-(3-methyl-2-butenyl)-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234426-43-8 CAPLUS
CN Sulfamide, N-[2-fluoro-2',5'-dimethoxy-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl][1,1'-biphenyl]-4-yl]-N'-methyl-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)



RN 234426-44-9 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 2-fluoro-2',5'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234426-46-1 CAPLUS
CN [1,1'-Biphenyl]-4-amine, N-cyclohexyl-2-fluoro-2',5'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234426-47-2 CAPLUS
CN Sulfamide, N-[2-fluoro-2',5'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl][1,1'-biphenyl]-4-yl]-N'-methyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 234426-48-3 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 2-chloro-N-(cyclohexylmethyl)-2',5'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234426-49-4 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 2-chloro-N-cyclohexyl-2',5'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234426-50-7 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 2-chloro-2',5'-dimethyl-N-(3-methyl-2-butenyl)-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234426-51-8 CAPLUS
CN [1,1'-Biphenyl]-4-amine, N-cyclopentyl-2-fluoro-2',5'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234426-52-9 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 2-fluoro-2',5'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 234426-53-0 CAPLUS
CN [1,1'-Biphenyl]-4-amine, N-[(4-ethylphenyl)methyl]-2-fluoro-2',5'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234426-54-1 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 2-fluoro-2',5'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]-N-[[4-(1-methylethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 234426-55-2 CAPLUS
CN Benzoic acid, 4-[[[2-fluoro-2',5'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl][1,1'-biphenyl]-4-yl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 234426-56-3 CAPLUS
CN Benzoic acid, 4-[[[2-fluoro-2',5'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl][1,1'-biphenyl]-4-yl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 234426-57-4 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 2,2',5'-trimethyl-N-(3-methyl-2-butenyl)-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234426-58-5 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 2',5'-dimethyl-N-(3-methyl-2-butenyl)-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234426-59-6 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 2',5'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]-N-2-propynyl- (9CI) (CA INDEX NAME)



RN 234426-60-9 CAPLUS
CN [1,1'-Biphenyl]-4-amine, N-(cyclohexylmethyl)-2',5'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234426-61-0 CAPLUS
CN [1,1'-Biphenyl]-4-amine, N-cyclohexyl-2',5'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234426-62-1 CAPLUS
CN 4-Pyridinemethanamine, N-[2',5'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)



RN 234426-63-2 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 2',5'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 234426-64-3 CAPLUS
CN Sulfamide, N-[2',5'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-

pyridinyl][1,1'-biphenyl]-4-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 234426-65-4 CAPLUS
CN 3-Thiophenemethanamine, N-[2',5'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)



RN 234426-66-5 CAPLUS
CN 3-Furanmethanamine, N-[2',5'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)



RN 234426-67-6 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 2',5'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234426-68-7 CAPLUS
CN [1,1'-Biphenyl]-4-amine, N,2',5'-trimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234426-69-8 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 2',3,5'-trimethyl-N-(3-methyl-2-butenyl)-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234426-70-1 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 2',3,5'-trimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 234426-71-2 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 3-fluoro-2',5'-dimethyl-N-(3-methyl-2-butenyl)-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234426-72-3 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 3-fluoro-2',5'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 234426-73-4 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 3-chloro-2',5'-dimethyl-N-(3-methyl-2-butenyl)-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234426-74-5 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 3-chloro-2',5'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 234426-75-6 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 3-methoxy-2',5'-dimethyl-N-(3-methyl-2-butenyl)-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234426-76-7 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 3-methoxy-2',5'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 234426-77-8 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 2',5'-dimethyl-N-(3-methyl-2-butenyl)-4'-[6-[(3-methyl-2-butenyl)oxy]-5-nitro-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234426-85-8 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 2-fluoro-2',5'-dimethyl-N-(3-methyl-2-butenyl)-4'-[2-methyl-6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234426-86-9 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 2-fluoro-2',5'-dimethyl-N-(3-methyl-2-butenyl)-4'-[5-methyl-6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234426-87-0 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 2-fluoro-2',5'-dimethyl-N-(3-methyl-2-butenyl)-4'-[4-methyl-6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234426-88-1 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 2-fluoro-2',5'-dimethyl-4'-[5-methyl-6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234426-89-2 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 2-fluoro-2',5'-dimethyl-4'-[4-methyl-6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234426-90-5 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 2',5'-dimethyl-N-(3-methyl-2-butenyl)-4'-[2-methyl-6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234426-91-6 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 2',5'-dimethyl-N-(3-methyl-2-butenyl)-4'-[5-methyl-6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234426-92-7 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 2',5'-dimethyl-N-(3-methyl-2-butenyl)-4'-[4-methyl-6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234426-93-8 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 2',5'-dimethyl-4'-[2-methyl-6-[(3-methyl-2-

butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234426-94-9 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 2',5'-dimethyl-4'-[5-methyl-6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234426-95-0 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 2',5'-dimethyl-4'-[4-methyl-6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234426-96-1 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 4'-[6-(2-fluoroethoxy)-3-pyridinyl]-2',5'-dimethyl-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)



RN 234426-97-2 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 2',5'-dimethyl-N-2-propynyl-4'-[6-(2-propynyloxy)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234426-98-3 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 2',5'-dimethyl-N-(3-methyl-2-butenyl)-4'-[6-(2-propenyloxy)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234427-05-5 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 2-fluoro-4'-[6-(2-furanylmethoxy)-3-pyridinyl]-2',5'-dimethyl-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)



RN 234427-10-2 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 4'-(6-methoxy-3-pyridinyl)-2',5'-dimethyl-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)



RN 234427-11-3 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 4'-(6-methoxy-5-nitro-3-pyridinyl)-2',5'-dimethyl-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)



RN 234427-14-6 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 2',3',5',6'-tetramethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234427-15-7 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 2',3',5',6'-tetramethyl-N-(3-methyl-2-butenyl)-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234427-16-8 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 2',3',5',6'-tetramethyl-N-(1-methylethyl)-4'-[6-

(2-propenyloxy)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234427-40-8 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 2'-methoxy-3',5',6'-trimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234427-41-9 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 2'-methoxy-3',5',6'-trimethyl-N-(3-methyl-2-butenyl)-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234427-42-0 CAPLUS
CN Benzoic acid, 4-[[[2'-methoxy-3',5',6'-trimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl][1,1'-biphenyl]-4-yl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

— OMe

RN 234427-43-1 CAPLUS
CN Benzoic acid, 4-[[[2'-methoxy-3',5',6'-trimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl][1,1'-biphenyl]-4-yl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 234427-44-2 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 2'-methoxy-3',5',6'-trimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]-N-[(3,4,5-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 234427-45-3 CAPLUS
CN 2-Furanmethanamine, N-[2'-methoxy-3',5',6'-trimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)



RN 234427-46-4 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 3'-methoxy-2',5',6'-trimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234427-47-5 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 3'-methoxy-2',5',6'-trimethyl-N-(3-methyl-2-butenyl)-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234427-48-6 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 3'-methoxy-2',5',6'-trimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 234427-49-7 CAPLUS

CN [1,1'-Biphenyl]-4-amine, N-cyclohexyl-3'-methoxy-2',5',6'-trimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234427-50-0 CAPLUS
CN 2-Furanmethanamine, N-[3'-methoxy-2',5',6'-trimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)



RN 234427-51-1 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 3'-methoxy-2',5',6'-trimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]-N-2-propynyl- (9CI) (CA INDEX NAME)



RN 234427-52-2 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 3'-methoxy-2',5',6'-trimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 234427-54-4 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 3'-methoxy-2',5',6'-trimethyl-N-(2-methyl-2-butenyl)-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234427-55-5 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 3'-methoxy-2',5',6'-trimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]-N-[(3,4,5-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 234427-56-6 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 4'-[6-(2-butenyloxy)-3-pyridinyl]-3'-methoxy-2',5',6'-trimethyl-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)



RN 234427-57-7 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 3'-methoxy-2',5',6'-trimethyl-N-(3-methyl-2-butenyl)-4'-[6-(3-pentenyloxy)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234427-58-8 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 3'-methoxy-2',5',6'-trimethyl-N-(3-methyl-2-butenyl)-4'-[6-(2-pentenyloxy)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234427-59-9 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 4'-[6-(2-butynyloxy)-3-pyridinyl]-3'-methoxy-2',5',6'-trimethyl-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)



RN 234427-60-2 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 4'-[6-(2-furanylmethoxy)-3-pyridinyl]-3'-methoxy-2',5',6'-trimethyl-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)



RN 234427-61-3 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 4'-[6-(2-furanylmethoxy)-3-pyridinyl]-3'-methoxy-

2',5',6'-trimethyl- (9CI) (CA INDEX NAME)



RN 234427-62-4 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 4'-[6-(2-fluoroethoxy)-3-pyridinyl]-3'-methoxy-2',5',6'-trimethyl-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)



RN 234427-63-5 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 3'-methoxy-2',5',6'-trimethyl-N-(3-methyl-2-butenyl)-4'-[6-(2,2,2-trifluoroethoxy)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234427-64-6 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 4'-[6-(2-furanylmethoxy)-3-pyridinyl]-3'-methoxy-2',5',6'-trimethyl-N-2-propynyl- (9CI) (CA INDEX NAME)



RN 234427-65-7 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 4'-[6-(2-butynyloxy)-3-pyridinyl]-3'-methoxy-2',5',6'-trimethyl-N-2-propynyl- (9CI) (CA INDEX NAME)



RN 234427-68-0 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 2',5'-dimethoxy-3',6'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234427-69-1 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 2',5'-dimethoxy-3',6'-dimethyl-N-(3-methyl-2-butenyl)-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234427-70-4 CAPLUS
CN Sulfamide, N-[2',5'-dimethoxy-3',6'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl][1,1'-biphenyl]-4-yl]-N'-methyl-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)



RN 234427-71-5 CAPLUS
CN [1,1'-Biphenyl]-4-amine, N-cyclohexyl-2',5'-dimethoxy-3',6'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234427-72-6 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 2',5'-dimethoxy-3',6'-dimethyl-N-(3-methyl-2-butenyl)-4'-[2-methyl-6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234427-73-7 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 2',5'-dimethoxy-3',6'-dimethyl-N-(3-methyl-2-butenyl)-4'-[5-methyl-6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234427-74-8 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 2',5'-dimethoxy-3',6'-dimethyl-N-(3-methyl-2-butenyl)-4'-[4-methyl-6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234427-80-6 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 2',3',6'-trimethyl-N-(3-methyl-2-butenyl)-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234427-81-7 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 2',3',6'-trimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 234427-82-8 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 2'-methoxy-5'-methyl-N-(3-methyl-2-butenyl)-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234427-83-9 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 2'-methoxy-5'-methyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 234427-84-0 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 2'-methoxy-5'-methyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 234427-85-1 CAPLUS
CN 1,4-Dioxaspiro[4.5]decan-8-amine, N-[2'-methoxy-5'-methyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)



RN 234427-86-2 CAPLUS
CN 2H-Pyran-4-amine, tetrahydro-N-[2'-methoxy-5'-methyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)



RN 234427-87-3 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 4'-[6-(2-furanylmethoxy)-3-pyridinyl]-2'-methoxy-5'-methyl-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)



RN 234427-88-4 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 4'-[6-(2-furanylmethoxy)-3-pyridinyl]-2'-methoxy-5'-methyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 234427-89-5 CAPLUS
CN 1,4-Dioxaspiro[4.5]decan-8-amine, N-[4'-[6-(2-furanylmethoxy)-3-pyridinyl]-2'-methoxy-5'-methyl[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)



RN 234427-90-8 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 6-methoxy-2,5-dimethyl-4'-[(3-methyl-2-butenyl)amino]-4-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]-, methyl ester

(9CI) (CA INDEX NAME)



RN 234427-91-9 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 4-[6-(2-furanylmethoxy)-3-pyridinyl]-6-methoxy-2,5-dimethyl-4'-[(3-methyl-2-butenyl)amino]-, methyl ester (9CI) (CA INDEX NAME)





RN 234427-92-0 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 3'-chloro-2',5',6'-trimethyl-N-(3-methyl-2-butenyl)-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234427-93-1 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 3'-chloro-2',5',6'-trimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 234427-94-2 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 3'-methoxy-2,2',5'-trimethyl-N-(3-methyl-2-butenyl)-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234427-95-3 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 3'-methoxy-2,2',5'-trimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 234427-96-4 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 2-fluoro-3'-methoxy-2',5'-dimethyl-N-(3-methyl-2-butenyl)-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234427-97-5 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2-fluoro-3'-methoxy-2',5'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 234427-98-6 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 3,5,6-trimethyl 4'-[(3-methyl-2-butenyl)amino]-4-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 234427-99-7 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4-[6-(2-furanylmethoxy)-3-pyridinyl]-3,5,6-trimethyl-4'-[(3-methyl-2-butenyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 234428-00-3 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 3,5,6-trimethyl-4'-[(3-methyl-2-butenyl)amino]-4-[6-(2-propynyloxy)-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 234428-54-7 CAPLUS
CN 2(1H)-Pyridinone, 5-(4'-amino-2'-fluoro-2,5-dimethyl[1,1'-biphenyl]-4-yl)-
(9CI) (CA INDEX NAME)



RN 234428-55-8 CAPLUS
CN 2(1H)-Pyridinone, 5-(4'-amino-2'-chloro-2,5-dimethyl[1,1'-biphenyl]-4-yl)-
(9CI) (CA INDEX NAME)



RN 234428-56-9 CAPLUS
CN 2(1H)-Pyridinone, 5-[2'-chloro-2,5-dimethyl-4'-[(3-methyl-2-
butenyl)amino][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)



RN 234428-57-0 CAPLUS
CN 2(1H)-Pyridinone, 5-[2'-fluoro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)



RN 234429-42-6 CAPLUS
CN Butanedioic acid, mono[[[[2',5'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl][1,1'-biphenyl]-4-yl](3-methyl-2-butenyl)amino]carbonyl]oxy]methyl] ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



IT **234429-28-8**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of tricyclic compds. as immunosuppressants and allergy inhibitors)
RN 234429-28-8 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 2-fluoro-2',5'-dimethyl-N-(3-methyl-2-butenyl)-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2003 ACS
AN 1997:341980 CAPLUS
DN 127:50541
TI 3-Pyridyloxymethyl heterocyclic ether compounds useful as nicotinic cholinergic ligands in controlling chemical synaptic transmission
IN Lin, Nan-horng; He, Yun; Holladay, Mark W.; Ryther, Keith; Li, Yihong
PA Abbott Laboratories, USA
SO U.S., 44 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5629325	A	19970513	US 1996-660044	19960606
	US 6127386	A	20001003	US 1997-844540	19970418
	WO 9746554	A1	19971211	WO 1997-US9167	19970604
	W: CA, JP, MX				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 934308	A1	19990811	EP 1997-927830	19970604
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	JP 2002515038	T2	20020521	JP 1998-500686	19970604
	US 6437138	B1	20020820	US 2000-472399	20000301
PRAI	US 1996-660044	A2	19960606		
	US 1997-844540	A	19970418		
	WO 1997-US9167	W	19970604		

OS MARPAT 127:50541
AB Novel 3-pyridyloxymethyl heterocyclic ether compds. I [n = 1-3; R1 = H, allyl, C1-6 alkyl; R2 = H, F, Cl, vinyl, Ph; L = bond, C1-6 alkylene, C.tplbond.C, (CH:CH)p, CO, CH2MCO; p = 1, 2; M = CH2, NH; R3 = H, C1-6 alkyl, alkoxy, (di)(alkyl)amino, Ph, naphthyl, certain heterocyclyl, etc.; with provisos] and their pharmaceutically acceptable salts and prodrugs are selective and potent ligands at neuronal nicotinic cholinergic channel receptors, and are effective in controlling synaptic transmission. For instance, (S)-1-methyl-2-pyrrolidinemethanol was etherified with 3,5-dibromopyridine using NaH in DMF, and the product monobromide was coupled with 1-hexyne using Pd(PPh3)2Cl2 and CuI, to give title compd. II. In a test for inhibition of neuronal nicotinic cholinergic channels in IMR-32 cells in vitro, II.2HCl gave 55% inhibition at 1 .mu.M.
IT **191161-87-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyridyloxymethyl heterocyclic ethers as nicotinic cholinergic agents)
RN 191161-87-2 CAPLUS
CN Pyridine, 5-(2-azetidinylmethoxy)-2-chloro-3-(4'-nitro[1,1'-biphenyl]-4-yl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


NH
S
O
N
Cl
NO2

```
=> d his

     (FILE 'HOME' ENTERED AT 16:42:42 ON 03 JUL 2003)

     FILE 'REGISTRY' ENTERED AT 16:42:47 ON 03 JUL 2003
L1             STRUCTURE UPLOADED
L2           0 S L1 SSS SAM
L3             STRUCTURE UPLOADED
L4           5 S L3 SSS SAM
L5             SCREEN 1840
L6             SCREEN 2016 OR  2026 OR  2039 OR  2040 OR  2045 OR  2047
L7             STRUCTURE UPLOADED
L8             QUE L7 AND L5 NOT L6
L9           3 S L8 SSS SAM
L10            SCREEN 1840
L11            SCREEN 2016 OR  2026 OR  2039 OR  2040 OR  2045 OR  2047
L12            STRUCTURE UPLOADED
L13            QUE L12 AND L10 NOT L11
L14          5 S L13 SSS SAM
L15            SCREEN 1840
L16            SCREEN 2016 OR  2026 OR  2039 OR  2040 OR  2045 OR  2047
L17            STRUCTURE UPLOADED
L18            QUE L17 AND L15 NOT L16
L19          3 S L18 SSS SAM
L20            SCREEN 1840
L21            SCREEN 2016 OR  2026 OR  2039 OR  2040 OR  2045 OR  2047
L22            STRUCTURE UPLOADED
L23            QUE L22 AND L20 NOT L21
L24         48 S L23 SSS SAM
L25            SCREEN 1840
L26            SCREEN 2016 OR  2026 OR  2039 OR  2040 OR  2045 OR  2047
L27            STRUCTURE UPLOADED
L28            QUE L27 AND L25 NOT L26
L29         35 S L28 SSS SAM
L30            SCREEN 1840
L31            SCREEN 2016 OR  2026 OR  2039 OR  2040 OR  2045 OR  2047
L32            STRUCTURE UPLOADED
L33            QUE L32 AND L30 NOT L31
L34          9 S L33 SSS SAM
L35        143 S L33 SSS FUL

     FILE 'CAPLUS' ENTERED AT 17:03:25 ON 03 JUL 2003
L36         10 S L35

     FILE 'CAOLD' ENTERED AT 17:04:02 ON 03 JUL 2003

=> s l35
L37          0 L35

=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.40     207.74

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -6.51
```

C:\STNEXP4\QUERIES\09980475 (amended - example).s



chain nodes :
13 39
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 16 17 18 19 20 21 22 23 24 25 26 27 28
29 30 31 32 33
chain bonds :
2-11 5-39 8-13
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 16-17 16-21 17-18
18-19 19-20 20-21 22-23 22-27 23-24 24-25 25-26 26-27 28-29 28-33 29-30 30-31
31-32 32-33
exact/norm bonds :
5-39 8-13
exact bonds :
2-11
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 16-17 16-21 17-18
18-19 19-20 20-21 22-23 22-27 23-24 24-25 25-26 26-27 28-29 28-33 29-30 30-31
31-32 32-33
isolated ring systems :
containing 1 : 7 : 16 : 22 : 28 :

G1:O,CH2,NH

G2:[*1],[*2],[*3]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 16:CLASS 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:CLASS 23:Atom
24:Atom 25:Atom 26:Atom 27:Atom 28:CLASS 29:Atom 30:Atom 31:Atom 32:Atom 33:Atom
39:CLASS
Element Count :

```
Node 13: Limited
    C,C5
    N,N1
    O,O0
    S,S0
```